S 3.1 COVID-19 pandemic
1. COVID-19 and history – a perspective from the great influenza pandemic of 1918
Speaker assigned (to be confirmed soon)
2. COVID-19 in Europe – clinical experience and learnings
Ron Gansevoort, Groningen, Netherlands
3. COVID-19 trials and vaccines – the future?
Martin Landray, Oxford, UK
S 3.2 News in glomerulonephritis treatment
1. IgA nephropathy: is immunosuppression needed?
Jürgen Floege, Aachen, Germany
2. Vasculitis and complement inhibition
Vladimir Tesar, Prague, Czeck Republic
3. GWAS in glomerular diseases
Speaker assigned (to be confirmed soon)
S 3.3 Membranous nephropathy: insights from recent clinical trials
1. The role of anti-PLA2R monitoring
Pierre Ronco, Paris, France
2. Rituximab as first line therapy
Giuseppe Remuzzi, Bergamo, Italy
3. Back to basics. Cyclophosphamide/steroids
Manuel Praga, Madrid, Spain
S 3.4 Onconephrology
1. High cut-off filters and multiple myeloma
Paul Cockwell, Birmingham, UK
2. Cancer immunotherapies (checkpoint inhibitors, CAR-T cells, IL-2) and the kidney
Laura Cosmai, Milan, Italy
3. Haemathological disorders in transplant recipients
Jolanta Malyszko, Warsaw, Poland
S 3.5 Complicated Lupus Nephritis
1. Management of refractory lupus nephritis
Speaker assigned (to be confirmed soon)
2. Urinary exosomal miRNA expression profile in lupus nephritis
Speaker assigned (to be confirmed soon)
3. Improved clarity of definitions and classification of glomerular lesions in lupus nephritis
Agnes Fogo, Nashville, TN, USA
S 3.6 ANCA vasculitis prognostic and treatment
1. ANCA vasculitis and treatment. Where are we now?
David Jayne, Cambridge, UK
2. Urinary CD163 in antineutrophil cytoplasm antibody-associated glomerulonephritis
Gema Fernandez-Juarez, Madrid, Spain
3. Renal risk score for ANCA vasculitis
Juan Manuel Mejia Vilet, Mexico
S 3.7 Kidney stones
1. From crystals to CKD
Felix Knauf, Berlin, Germany
2. Urate transporters, gout and urate nephropathy
Olivier Bonny, Lausanne, Switzerland
3. ABC of Randall’s plaques and stones: from rare diseases to calcium nephrolithiasis
Emmanuel Letavernier, Paris, France
S 3.8 Up-to-Date on Alport Syndrome
1. Different genes for different basement defects: genotype/phenotype correlations
Rachel Lennon, Manchester, UK
2. Ongoing clinical trials
Michelle Rheault, Minneapolis, MN, USA
3. New pathogenetic mechanisms and therapeutic implications
Alessia Fornoni, Miami, FL, USA
S 3.9 The nephrotoxicity of commonly used medications: what is the evidence and what are the alternatives
1. Proton pump inhibitors
Laurie A Tomlinson, London, UK
2. Oral anticoagulants
Sergey Brodsky, Columbus, OH, USA
3. Paracetamol
Speaker assigned (to be confirmed soon)
ML 3.1 Kidney transplant suitability for patients with prior cancers: what the nephrologist should know?
Alicja Dębska-Ślizień, Gdańsk, Poland
ML 3.2 C3 glomerulonephritis and membranoproliferative glomerulonephritis: different diseases, same treatment?
Marina Noris, Bergamo, Italy
ML 3.3 Kidney allograft fibrosis: what we have learned from latest translational research studies
Daniel Seron, Barcelona, Spain
ML 3.4 Update on diagnosis and therapy for non-AL amyloidosis
Tamer Rezk, London, UK
ML 3.5 Bardet-Biedle Syndrome: from clinic to omics
Miriam Zacchia, Naples, Italy
ML 3.6 Pathogenesis and management of nephrotic syndrome
Speaker assigned (to be confirmed soon)
ML 3.7 Leveraging animal models for onconephrology research
Anna Capasso, Austin, TX, USA